XFOR
HealthcareX4 Pharmaceuticals, Inc.
$3.84
$-0.05 (-1.29%)
Jan 5, 2026
Price History (1Y)
Analysis
X4 Pharmaceuticals, Inc. is a healthcare company in the biotechnology industry with a market capitalization of $335.76 million. It employs 143 people and operates within the broader sector of healthcare. The company's financial health reveals significant losses, as indicated by net income of -$95.095 million and EBITDA of -$90.372 million over the trailing twelve months (TTM). Profit margins are also negative at -279.9%, while operating margin is -1281.0%. Returns on equity and assets are similarly unimpressive, standing at -156.9% and -33.5%, respectively. However, the company's debt-to-equity ratio of 125.54 highlights its substantial leverage, while cash levels stand at $122.19 million against a debt burden of $77.36 million. X4 Pharmaceuticals' valuation is characterized by a negative forward P/E ratio of -3.56 and an EV/EBITDA multiple of -3.22. The company's revenue growth rate over the past year was 215.2%, although earnings growth data is unavailable.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $335.76M
- P/E Ratio
- N/A
- 52-Week High
- $24.42
- 52-Week Low
- $1.35
- Avg Volume
- 1.03M
- Beta
- 0.41
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 143